top of page

Rationale

Sustained exposure can unlock the potential of proven pharmacology.

Many therapeutically compelling molecules are limited by pharmacokinetic properties that constrain efficacy. Piston Bio is developing extended half-life medicine designed to provide sustained therapeutic exposure while building on established pharmacology and clinical experience.

good pk 1111.png

Our Approach

gook pk 2222.png

From validated biology to meaningful impact.

Piston Bio develops extended half-life versions of clinically characterized medicine through a focused, capital-efficient development strategy designed to create differentiated therapies for patients with cancer.

good our approach 11.png
good our approach 22.png

Piston Bio

New medicine for cancer and autoimmune disease.

Small molecules and biologics for the mind and body.

Small molecules have a big repertoire.

Inside a Glowing Cancer Cell.png

Mind and body are inseparable.

Neural Pathways to Tumor Biology.png

Biologics are on deck.

Gemini_Generated_Image_ar0yxcar0yxcar0y.jpeg

100% owned

Pipeline

PST-102

non-binding licensing terms agreed with Roche

mosperafenib

BRAF V600E inhibitor - oncology

A2A antagonist - oncology/CNS

PST-101

TLR7/8 agonist - oncology

100% owned

PST-102 Antitumor Immune Response.png
PST-101_ Blocking A2A, Restoring Motivation.png
Mosperafenib Antitumor Activity Infographic.png
Company Presentation
Contact Us
bottom of page